Repligen (NASDAQ:RGEN) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Repligen (NASDAQ:RGEN) from a sell rating to a hold rating in a research report report published on Friday morning.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. upped their price target on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. UBS Group reduced their price target on Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research report on Wednesday, July 31st. Stephens reiterated an “overweight” rating and issued a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. Benchmark restated a “hold” rating on shares of Repligen in a research report on Monday, August 5th. Finally, Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They set an “overweight” rating and a $180.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $190.25.

Repligen Stock Performance

Shares of RGEN opened at $142.58 on Friday. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13. The business has a 50-day simple moving average of $140.20 and a two-hundred day simple moving average of $143.62. The company has a quick ratio of 5.56, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter in the prior year, the firm earned $0.23 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. As a group, analysts predict that Repligen will post 1.52 EPS for the current year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is owned by company insiders.

Institutional Trading of Repligen

Several institutional investors and hedge funds have recently modified their holdings of RGEN. O Shaughnessy Asset Management LLC raised its stake in shares of Repligen by 6.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 1,924 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 125 shares during the last quarter. UniSuper Management Pty Ltd raised its stake in shares of Repligen by 100.0% in the first quarter. UniSuper Management Pty Ltd now owns 800 shares of the biotechnology company’s stock worth $147,000 after purchasing an additional 400 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of Repligen by 1.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 38,559 shares of the biotechnology company’s stock worth $7,086,000 after purchasing an additional 567 shares during the last quarter. Advisors Asset Management Inc. raised its stake in shares of Repligen by 21.6% in the first quarter. Advisors Asset Management Inc. now owns 13,827 shares of the biotechnology company’s stock worth $2,543,000 after purchasing an additional 2,456 shares during the last quarter. Finally, Lazard Asset Management LLC raised its stake in shares of Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.